Copenhagen - Free Realtime Quote DKK

Zealand Pharma A/S (ZEAL.CO)

235.50 +1.30 (+0.56%)

As of 12:04:41 PM GMT+1. Market Open.

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

Zealand Pharma announces positive topline results from the multiple ascending dose part of Phase 1 trial with Kv1.3 ion channel blocker ZP9830

GlobeNewswire 16d ago

ZEAL.CO
+0.56%
Has Zealand Pharma (CPSE:ZEAL) Fallen Enough To Look Cheap On Earnings?

Simply Wall St. 25d ago

ZEAL.CO
+0.56%
ROP.SW
Zealand Pharma (CPSE:ZEAL) Could Be 43% Undervalued After Phase 2 Trial Success

Simply Wall St. 25d ago

ZEAL.CO
+0.56%
Zealand Pharma (CPSE:ZEAL) Reports Positive Phase 2 Petrelintide Results In Type 2 Diabetes

Simply Wall St. 26d ago

ZEAL.CO
+0.56%
Zealand Pharma announces positive Phase 2 ZUPREME-2 topline results for amylin analog petrelintide in people with overweight or obesity and type 2 diabetes

GlobeNewswire 27d ago

ZEAL.CO
+0.56%
Zealand Pharma – Completion of share buy-back program and related transactions (week 40 and 41, 2026)

GlobeNewswire 29d ago

ZEAL.CO
+0.56%
DANSKE.CO
Zealand Pharma Reports 13.1% Weight Loss in Phase 3 Survodutide Trial

PREMIUM
MT Newswires 1mo ago

ZEAL.CO
+0.56%
Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes

GlobeNewswire 1mo ago

ZEAL.CO
+0.56%
Total number of shares and voting rights in Zealand Pharma as of September 30, 2026

GlobeNewswire 1mo ago

ZEAL.CO
+0.56%
Zealand Pharma to present additional data from Phase 2 ZUPREME-1 trial for petrelintide at EASD 2026 and announces publication of trial results in The Lancet Diabetes & Endocrinology

GlobeNewswire 1mo ago

ZEAL.CO
+0.56%
Zealand Pharma - Transactions related to share buy-back program (week 39, 2026)

GlobeNewswire 1mo ago

ZEAL.CO
+0.56%
Zealand Pharma announces initiation of the registrational Phase 3 ZUPREME program of petrelintide in people with overweight or obesity

GlobeNewswire 1mo ago

ZEAL.CO
+0.56%

Performance Overview

Return	ZEAL.CO	OMX Copenhagen 25 Index (^OMXC25)
YTD	-49.51%	+11.17%
1-Year	-52.96%	+20.24%
3-Year	-22.79%	+24.05%

U.S. markets open in 3h 12m

Zealand Pharma A/S (ZEAL.CO)

Zealand Pharma announces positive topline results from the multiple ascending dose part of Phase 1 trial with Kv1.3 ion channel blocker ZP9830

Has Zealand Pharma (CPSE:ZEAL) Fallen Enough To Look Cheap On Earnings?

Zealand Pharma (CPSE:ZEAL) Could Be 43% Undervalued After Phase 2 Trial Success

Zealand Pharma (CPSE:ZEAL) Reports Positive Phase 2 Petrelintide Results In Type 2 Diabetes

Zealand Pharma announces positive Phase 2 ZUPREME-2 topline results for amylin analog petrelintide in people with overweight or obesity and type 2 diabetes

Zealand Pharma – Completion of share buy-back program and related transactions (week 40 and 41, 2026)

Zealand Pharma Reports 13.1% Weight Loss in Phase 3 Survodutide Trial

Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes

Total number of shares and voting rights in Zealand Pharma as of September 30, 2026

Zealand Pharma to present additional data from Phase 2 ZUPREME-1 trial for petrelintide at EASD 2026 and announces publication of trial results in The Lancet Diabetes & Endocrinology

Zealand Pharma - Transactions related to share buy-back program (week 39, 2026)

Zealand Pharma announces initiation of the registrational Phase 3 ZUPREME program of petrelintide in people with overweight or obesity